Investment Rating - The report assigns a "Buy" rating to Tencent (700 HK) and NetEase (NTES US) with target prices of 700.0 and 155.0 respectively, indicating potential upside from current prices [3][4]. Core Insights - Tencent's mobile game revenue showed stability year-on-year, with significant contributions from new games like "Delta Action" and "Clash Royale," offsetting the impact of high base figures from previous titles [4][12]. - NetEase's overseas new games contributed to revenue growth, with a slight increase in domestic revenue driven by new titles [4][15]. - The report highlights the ongoing strong performance of Tencent's evergreen games and the potential for new game releases to drive future revenue growth [4][12]. Summary by Sections Mobile Game Performance - Tencent's domestic mobile game revenue decreased by 27 million yuan (8%) year-on-year, primarily due to high base effects from "MDnF," partially offset by new games [12]. - "Delta Action" achieved a record revenue of 1.5 billion yuan in September, driven by user growth [12]. - NetEase's domestic mobile game revenue slightly increased by 0.7 million yuan (1%), supported by new titles [15]. Overseas Revenue - Tencent's overseas revenue increased by 6.7 million yuan (9%) year-on-year, mainly due to "Clash Royale" and other titles [17]. - NetEase's overseas revenue grew by 1.6 million yuan (18%), benefiting from new game launches [17]. Game Approval and New Releases - In September 2025, 145 domestic and 11 imported game licenses were issued, indicating a stable supply of new games [25]. - The report emphasizes the importance of upcoming titles from Tencent and NetEase, which are expected to enhance their market positions [28].

Group 1: Core Insights - The technology sector has outperformed the market recently, with significant valuation growth in A-share technology stocks, driven primarily by optimism surrounding AI's prospects beyond 2026 [1] - Strong price increases in storage components are expected to continue, with DRAM prices projected to remain robust until Q3 2026 and NAND prices expected to hold strong until H1 2026 [1] - The import value of semiconductor manufacturing equipment continued to grow year-on-year in August, indicating ongoing investment from domestic semiconductor manufacturers [1] Group 2: Semiconductor Industry - The forecast for China's semiconductor equipment sales in 2025 is maintained at USD 52 billion, reflecting a 5% year-on-year growth [1] - TSMC's revenue in September continued to grow by over 30%, supported by its technological advantages in 2nm and A16, which are expected to drive rapid growth in AI-related revenues [1] Group 3: Investment Recommendations - The valuation levels of covered US semiconductor companies are considered relatively manageable, with a positive outlook on the trend of domestic substitution and AI infrastructure development benefiting domestic wafer foundries [2] - The rating for SMIC has been upgraded to "Buy" with a target price raised to HKD 90, while the target price for Hua Hong Semiconductor has also been increased to HKD 90, maintaining a "Buy" rating [2]

Investment Rating - The automotive industry is rated as "Leading" with expectations for strong performance in the upcoming quarter [1]. Core Insights - In September, the penetration rate of new energy vehicles (NEVs) reached 57.8%, indicating a positive outlook for sales in the fourth quarter [1][3]. - The retail sales of passenger vehicles in September reached 2.241 million units, marking a year-on-year increase of 9.2% for the first nine months of 2025 [3]. - The report highlights that domestic brands outperformed the industry, capturing a retail market share of 66.9% in September [3]. Summary by Sections Industry Performance - The retail sales of new energy passenger vehicles in September were 1.296 million units, with a penetration rate of 57.8%, up 5.0 percentage points year-on-year [3]. - The export of passenger vehicles totaled 528,000 units in September, with a significant increase in NEV exports [3]. Company Valuation Overview - Companies such as CATL, BYD, and Xpeng Motors are rated as "Buy" with target prices indicating potential upside [2][11]. - The average price-to-earnings ratio for the covered companies is projected to be 30.9 for FY25E [2]. Investment Recommendations - The report suggests focusing on companies like Xpeng Motors and Geely for their upcoming product launches and internal resource integration [3]. - It is advised to remain cautious as the market may enter a consumption lull after the fourth quarter sales surge [3].

Global Macro - The report indicates that the likelihood of the proposed large-scale tariff increases by the US on China is low, despite recent announcements by President Trump regarding a 100% tariff increase on certain exports starting November 1, 2025 [3][4] - It is expected that both parties will likely reach a de-escalation arrangement during the upcoming summit, which would stabilize trade relations and create conditions for further economic stability [3][4] - Short-term fluctuations in Chinese assets are anticipated, but these should not alter the medium-term bullish trend, presenting potential buying opportunities [4] Automotive Industry - In September 2025, the penetration rate of new energy vehicles (NEVs) reached 57.8%, with retail sales of passenger vehicles hitting a record high of 2.241 million units, reflecting a year-on-year increase of 6.3% [5][7] - The export of passenger vehicles, including NEVs, maintained a strong growth momentum, with total exports reaching 528,000 units in September, a year-on-year increase of 20.7% [5][7] - The report suggests that the upcoming adjustment of the new energy vehicle purchase tax policy in 2026 is likely to stimulate consumer purchases before the end of the year, particularly during the peak sales season [7] - Investors are advised to remain cautious as the market may enter a consumption lull after the fourth quarter sales surge, with specific attention to stock price fluctuations in the sector [7]

Investment Rating - The report maintains a "Buy" rating for several companies in the real estate sector, including New World Development (9.70 HK), China Resources Land (35.30 HK), and Yuexiu Property (10.70 HK) [3][4][12]. Core Insights - The overall real estate market showed signs of recovery in September 2025, with total sales from the top 100 developers increasing by 20.9% month-on-month to 266.1 billion RMB [4][12]. - The report highlights that state-owned enterprises (SOEs) dominate the sales rankings, with nine out of the top ten developers being SOEs, and Poly Developments maintaining the top position [4][12]. - The central government continues to implement policies aimed at stabilizing the real estate market, focusing on urban renewal and improving housing standards [4][14][35]. Summary by Sections Market Performance - The report indicates that the stock performance of Chinese enterprises has generally outperformed that of mainland developers, with the industry net asset value discount slightly narrowing to 83.7% [5][12]. Sales Performance - In September 2025, the sales of 21 tracked listed developers increased by 4.4% month-on-month, driven by significant growth from China Resources Land and Jianfa Properties, which saw increases exceeding 30% [12][13]. - The average selling price rose by 13.7% month-on-month, while the sales area decreased by 9.1% [12][13]. Market Dynamics - The report notes a 14.75% month-on-month increase in new home transaction volumes across ten cities in September, with supply rising by 42.5% [21][22]. - The inventory turnover period has expanded to approximately 19.13 months, indicating a need for further market adjustments [21][22]. Policy Review - Central policies in September 2025 focused on stabilizing the real estate market, enhancing housing support, and promoting urban renewal projects [35][37]. - Local governments have introduced measures to lower purchasing thresholds and optimize credit support to stimulate market demand [37][38]. Company Updates - Kaisa Group's offshore debt restructuring became effective, involving the issuance of new notes totaling 6.686 billion USD [39]. - China Resources Land reported a significant increase in contract sales, reflecting its strong market position [4][12]. - Poly Developments is actively engaging in asset-backed securities projects to optimize its capital structure [45].

Group 1: Core Insights - The real estate market showed signs of recovery in September 2025, with total sales from the top 100 developers increasing by 20.9% month-on-month to 266.1 billion RMB [1] - The average sales price for the 21 tracked major listed developers rose by 13.7% month-on-month in September [1] - Central policies aimed at stabilizing the real estate market are expected to continue, with a focus on urban renewal and improving housing standards, leading to a gradual recovery in transaction volumes in October [1] Group 2: Company-Specific Insights - The secondary market demand is anticipated to improve and outperform the primary market, with a positive outlook for China Resources Land (1109 HK) and Yuexiu Property (123 HK), both of which have demonstrated strong sales performance and execution capabilities in recent years [2]

Core Insights - The report highlights that foreign capital continues to invest in high-cost performance targets within the pharmaceutical sector, suggesting a focus on catalysts and undervalued quality innovation opportunities in Q4 [1][2] - The Hang Seng Healthcare Index increased by 3.1% this week, outperforming the broader market, with medical devices, biopharmaceuticals, and prescription drugs showing superior performance [1] - There is a notable increase in domestic capital holdings in pharmaceutical stocks through the Hong Kong Stock Connect since September, while foreign holdings have slightly decreased since mid-year, indicating a sustained interest in innovative drugs [1][2] Market Review - The report indicates that foreign investors have been increasing their positions in high-cost performance innovative drug targets and service-related companies, particularly those benefiting from potential interest rate cuts and "AI + healthcare" concepts [1] - The upcoming Nobel Prize in Physiology or Medicine awarded for research in Treg and peripheral immune tolerance is expected to further stimulate investment interest in related innovative drug companies [2] - The ESMO conference scheduled for mid to late October is highlighted as a key event, with recommendations to focus on companies like Kangfang Biotech, Kelun-Biotech, Rongchang Biopharma, and Hengrui Medicine, which are expected to release significant data [2] Investment Recommendations - The report recommends focusing on specific segments within the pharmaceutical industry, including: 1. Innovative drugs: Companies like 3SBio and Eucure Biopharma are noted for having rich short-term catalysts and valuations that do not yet reflect the value of their core products [2] 2. CXO: Companies benefiting from high downstream demand and marginal recovery in financing, such as WuXi AppTec, are highlighted as key players in this segment [2]

Group 1: Core Insights - AMD's collaboration with OpenAI is expected to enhance its industry position significantly, with a target price increase to $248, indicating a potential upside of 17.3% from the current closing price of $211.51 [1] - The partnership involves AMD providing AI computing products based on the MI450 series chips and Helios cabinet solutions, laying the groundwork for the Instinct series GPUs to become a mainstream solution in the industry [1][2] - AMD's projected revenue from the first gigawatt (GW) deployment is estimated to be between $15 billion and $21 billion, primarily expected to be realized before 2027 [2] Group 2: Financial Projections - AMD's revenue forecasts for 2026 and 2027 have been raised to $42.2 billion and $55.8 billion, respectively, up from previous estimates of $38.8 billion and $43.9 billion [2] - Non-GAAP EPS estimates for 2026 and 2027 have also been increased to $6.16 and $8.76, respectively, compared to earlier projections of $5.60 and $6.51 [2] - The issuance of warrants or stock options to OpenAI is anticipated, with AMD potentially issuing up to 16 million shares (approximately 10% of its equity) at a price of $0.01 per share by October 2030 [2]

交银国际研究 每日晨报 2025 年 10 月 8 日 今日焦点 | 新世界发展 | | 17 HK | | --- | --- | --- | | 合约销售稳健，再融资落地助力财务优化；上 | | 评级: 买入 | | 调目标价 | | | | 收盘价: 港元 8.21 | 目标价: 港元 9.70↑ | 潜在涨幅: +18.1% | | 谢骐聪, CFA, FRM | philip.tse@bocomgroup.com | | 2025 财年业绩大致符合预期，收入为 276.8 亿港元，同比降 23%。扣除 拨备及其他一次性非现金影响，来自持续经营业务之核心盈利，核心经 营利润为 60.2 亿港元，同比下降 13%，我们估算核心利润约为 5 亿港 元，稍低于预期。 2025 年公司香港实现应占合约销售约 110 亿港元，并在中国内地物业取 得合约销售为人民币 140 亿元。公司设定 2026 财年全年销售目标为 270 亿港元，同比增加 4%。 2025 财年净负债约为 1,201 亿港元，同比减少约 45 亿港元，同时短期 债务减少至约 66 亿港元。公司于 2025 年 6 月成功完成 882 亿港元 ...

Core Insights - The report highlights an increasing investment trend from both domestic and foreign investors in service-oriented companies and innovative pharmaceutical firms, particularly in the context of anticipated interest rate cuts in Q4 [1][2] - The Hang Seng Healthcare Index rose by 2.2% this week, underperforming the broader market, with CXO, biopharmaceuticals, and traditional Chinese medicine sectors showing better performance [1] Investment Insights - The upcoming ESMO conference in mid-October is expected to provide significant data releases from companies such as Kangfang Biotech, Kelun-Biotech, and Rongchang Biotech, which are recommended for close monitoring [2] - With an increase in industry catalysts starting in October, the market is anticipated to rebound, focusing on the following segments: 1. Innovative drugs: Companies like 3SBio and Eucure Biopharma have rich short-term catalysts, and their valuations do not yet reflect the value of core blockbuster products. Companies like Sinopharm and Legend Biotech are considered undervalued with clear long-term growth logic [2] 2. CXO: Leading companies in this segment are expected to benefit from high downstream demand and marginal improvements in financing conditions, such as WuXi AppTec [2]